Prevalence and clinical characteristics of oral lesions in heart transplant patients induced by sirolimus and everolimus: a systematic review and meta-analysis on a global scale

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
MOURA, Anne Evelyn Oliveira
BESSELER, Mariana Oliveira
PEREZ-DE-OLIVEIRA, Maria Eduarda
NORMANDO, Ana Gabriela Costa
NEVES, Itamara Lucia Itagiba
NEVES, Ricardo Simoes
VARGAS, Pablo Agustin
SANTOS-SILVA, Alan Roger
Citação
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, v.137, n.1, p.37-52, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. Sirolimus (SRL) and everolimus (EVL) are increasingly included in immunosuppressive protocols after heart transplantation. They present some side effects, including the appearance of painful lesions in the oral cavity. Therefore, this systematic review aimed to verify the global prevalence and clinical characteristics of oral lesions induced by SRL and EVL in heart transplant patients.Study Design. A systematic review was performed using 5 main electronic databases (Medline/PubMed, SCOPUS, EMBASE, Web of Science, and LILACS), in addition to the gray literature. Studies were independently assessed by 2 reviewers based on established eligibility criteria. The risk of bias was assessed using the Joanna Briggs Institute appraisal tools, and the certainty of evidence was evaluated through GRADE assessment.Results. Seventeen studies (860 patients) were included in the qualitative analysis. Of these, 11 studies were pooled in a metaanalysis of prevalence. The worldwide prevalence of oral lesions induced by SRL and EVL in heart transplant patients was 10.0%, and most lesions were described as ulcers >1.0 cm, related to significant pain.Conclusions. Oral lesions induced by SRL and/or EVL, although not very prevalent, have a relevant impact on patient's lives and the continuity of treatment.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59290
Referências
  1. Aranda-Dios A, 2006, TRANSPL P, V38, P2547, DOI 10.1016/j.transproceed.2006.08.075
  2. Asante-Korang A, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.13054
  3. Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38
  4. Baur B, 2011, TRANSPL P, V43, P1853, DOI 10.1016/j.transproceed.2011.01.174
  5. Chinnock TJ, 2011, PEDIATR TRANSPLANT, V15, P746, DOI 10.1111/j.1399-3046.2011.01566.x
  6. Chuang P, 2007, AM J TRANSPLANT, V7, P714, DOI 10.1111/j.1600-6143.2006.01678.x
  7. de Oliveira MA, 2011, ORAL ONCOL, V47, P998, DOI 10.1016/j.oraloncology.2011.08.009
  8. Delgado JF, 2009, TRANSPL P, V41, P3835, DOI 10.1016/j.transproceed.2009.06.236
  9. Eisen HJ, 2013, AM J TRANSPLANT, V13, P1203, DOI 10.1111/ajt.12181
  10. Ferté C, 2011, EUR J CANCER, V47, P2249, DOI 10.1016/j.ejca.2011.03.017
  11. Legert KG, 2021, ORAL DIS, V27, P1217, DOI 10.1111/odi.13663
  12. González-Vílchez F, 2008, J HEART LUNG TRANSPL, V27, P1135, DOI 10.1016/j.healun.2008.07.020
  13. Grelli I, 2013, Ann Stomatol (Roma), V4, P22
  14. Grimm K, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14191
  15. Groetzner J, 2004, EUR J CARDIO-THORAC, V25, P333, DOI 10.1016/j.ejcts.2003.11.030
  16. Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
  17. Hoff K., 2015, RFO UPF, V20, P319
  18. Lobach NE, 2005, J HEART LUNG TRANSPL, V24, P184, DOI 10.1016/j.healun.2004.11.005
  19. Mahé E, 2005, TRANSPLANTATION, V79, P476, DOI 10.1097/01.TP.0000151630.25127.3A
  20. Michel S, 2013, EXP CLIN TRANSPLANT, V11, P429, DOI 10.6002/ect.2013.0036
  21. Moola S, 2017, JBI manual for evidence synthesis, P5, DOI 10.46658/JBIMES-20-08
  22. Moura AEO, 2022, PROSPERO
  23. Murad M Hassan, 2017, Evid Based Med, V22, P85, DOI 10.1136/ebmed-2017-110668
  24. Nguyen LS, 2019, DRUG SAFETY, V42, P813, DOI 10.1007/s40264-019-00810-9
  25. Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
  26. Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n160
  27. Peterson DE, 2016, CANCER MED-US, V5, P1897, DOI 10.1002/cam4.761
  28. Sallam K, 2021, ANN TRANSPL, V26, DOI 10.12659/AOT.923536
  29. Sasaoka T, 2010, TRANSPL P, V42, P3700, DOI 10.1016/j.transproceed.2010.06.023
  30. Scully C, 2008, BRIT J ORAL MAX SURG, V46, P198, DOI 10.1016/j.bjoms.2007.07.201
  31. Scully C, 2006, NEW ENGL J MED, V355, P165, DOI 10.1056/NEJMcp054630
  32. Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647
  33. Siegel M A, 1999, J Calif Dent Assoc, V27, P210
  34. Sonis S, 2010, CANCER-AM CANCER SOC, V116, P210, DOI 10.1002/cncr.24696
  35. Spehl MS, 2018, PEDIATR TRANSPLANT, V22, DOI 10.1111/petr.13072
  36. Thibodeau JT, 2013, CLIN TRANSPLANT, V27, P945, DOI 10.1111/ctr.12269
  37. Vermeulen T, 2010, ACTA CHIR BELG, V110, P339, DOI 10.1080/00015458.2010.11680629
  38. Villa A, 2015, BIOL BLOOD MARROW TR, V21, P503, DOI 10.1016/j.bbmt.2014.11.680
  39. Zuckermann A, 2012, AM J TRANSPLANT, V12, P2487, DOI 10.1111/j.1600-6143.2012.04131.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor